ReviewFrontiers in pharmacology2026
Epithelial-mesenchymal transition and sunitinib resistance in renal cell carcinoma: mechanisms and therapeutic strategies.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal cell carcinoma (RCC) is a prevalent, highly aggressive malignant tumor that affects the urinary system. RCC has a pronounced propensity for metastasis. Despite the widespread use of sunitinib as first-line therapy for advanced RCC, the occurrence of primary and acquired resistance is frequent and presents significant challenges for effective clinical management. Epithelial-mesenchymal transition (EMT) induction is mediated by hypoxia-HIF signaling, chronic inflammatory stimulation, stromal-tumor cell interactions, and metabolic reprogramming, which confers increased cellular plasticity, migratory potential, and survival benefits. EMT activation is closely associated with reorganization of cellular signaling networks under tumor microenvironment stress, the initiation of alternative angiogenic pathways, and the enhanced anti-apoptotic capacity, all of which contribute to the development of sunitinib resistance. This review systematically summarizes current evidence involving the molecular basis of EMT-driven sunitinib resistance in RCC and investigates potential therapeutic targets, establishing a conceptual foundation for the development of novel strategies to counteract resistance and enhance clinical efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.